Hims & Hers

Hims & Hers Confronts a Three-Way Squeeze as Earnings Approach

April 26, 2026

Hims & Hers: A Valuation Paradox Ahead of Earnings

Brett Shapiro - April 14, 2026

Hims & Hers: The Costly Pivot to Brand-Name Weight Loss Drugs

April 9, 2026

Hims & Hers Faces Competitive Pressure Following Novo Nordisk Launch

April 3, 2026

Regulatory Shifts and Strategic Partnership Fuel Hims & Hers Stock Surge

kashif hafeez - April 1, 2026

Legal Scrutiny Clouds Operational Progress at Hims & Hers

Brett Shapiro - March 31, 2026

Hims & Hers Pivots from Copycat Drugs to Branded Weight-Loss Treatments

Brett Shapiro - March 25, 2026

Hims & Hers Forges Direct Supply Deal with Novo Nordisk for Weight-Loss Drugs

angelina - March 18, 2026

Hims & Hers Shares Surge on Major Strategic Shifts

angelina - March 15, 2026

Hims & Hers Stock Surges on Strategic Pivot and Legal Settlement

kashif hafeez - March 13, 2026

Regulatory Headwinds and Disappointing Guidance Plague Hims & Hers Stock

February 26, 2026

Hims & Hers Faces Regulatory and Legal Challenges

angelina - February 17, 2026

Hims & Hers Bets Big on Provocative Super Bowl Ad Amid Stock Slide

kashif hafeez - February 2, 2026

Hims & Hers Bets Big on Super Bowl Ad to Champion Healthcare Equity

kashif hafeez - January 30, 2026

Hims & Hers Faces a Stark Growth Deceleration

January 26, 2026

12 3 Page 1 of 3